Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 2

Enfuvirtide antiretroviral therapy in HIV-1 infection

Authors Kitchen CMR, Nuño M, Kitchen SG, Krogstad P

Published 11 April 2008 Volume 2008:4(2) Pages 433—439


Christina MR Kitchen1, Miriam Nuño1, Scott G Kitchen2, Paul Krogstad3

1Department of Biostatistics, UCLA School of Public Health, Los Angeles, CA USA; 2Department of Hematology and Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA USA; 3Departments of Pediatrics and Medical Molecular Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA

Abstract: It has been over 25 years since the first diagnosis of what would be known as AIDS. Although great strides in anti-HIV therapeutics have been made, there is still a great need for antiretrovirals that are effective against drug-resistant HIV. Enfuvirtide (ENF) is the first of a new class of fusion inhibitors to be approved by the US Food and Drug Administration for use in combination with other antiretroviral agents among HIV-1 infected patients with previous treatment experience. The inclusion of enfuvirtide in an optimized antiretroviral background regimen for the treatment of HIV-1 infected (treatment-experienced) patients followed the success of two critical clinical trials (TORO: T20 vs Optimized Regimen Only I and II). Even though injection-site reactions persisted in these trials, improved virological and immunological responses were observed among patients. Challenges associated with ENF treatment include the high cost of the drug, injection-site reactions, determining the optimal time to initiate treatment, and the potential for the selection of drug resistant mutants and viral evolution. ENF is a promising novel treatment for HIV infected individuals whose choices for effective treatment are limited by previous treatment and resistance. Understanding the implications of viral fitness and evolution in the presence of ENF treatment is crucial in determining effective and safe treatment regimens, particularly among treatment-experienced patients.

Keywords: enfuvirtide, HIV, salvage therapy, drug resistance, gp41, evolution

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 


Readers of this article also read:

Formation of curcumin nanoparticles via solution-enhanced dispersion by supercritical CO2

Zhao Z, Xie M, Li Y, Chen A, Li G, Zhang J, Hu H, Wang X, Li S

International Journal of Nanomedicine 2015, 10:3171-3181

Published Date: 29 April 2015

Denileukin diftitox for the treatment of cutaneous T-cell lymphoma

David Kaminetzky, Kenneth B Hymes

Biologics: Targets and Therapy 2008, 2:717-724

Published Date: 5 December 2008

A review of nasal polyposis

Jonathan Ray Newton, Kim Wong Ah-See

Therapeutics and Clinical Risk Management 2008, 4:507-512

Published Date: 11 April 2008

Fixed combination therapies in COPD – effect on quality of life

Beatrix Groneberg-Kloft, Axel Fischer, Tobias Welte

International Journal of Chronic Obstructive Pulmonary Disease 2007, 2:551-557

Published Date: 15 January 2008

Early diagnosis of oral cancer based on the surface plasmon resonance of gold nanoparticles

James Chen Yong Kah, Kiang Wei Kho, Caroline Guat Leng Lee, Colin James Richard Sheppard, Ze Xiang Shen, et al

International Journal of Nanomedicine 2007, 2:785-798

Published Date: 15 January 2008

Review of biphasic insulin aspart in the treatment of type 1 and 2 diabetes

Nazia Raja-Khan, Sarah S Warehime, Robert A Gabbay

Vascular Health and Risk Management 2007, 3:919-935

Published Date: 15 January 2008

Prevention and treatment of venous thromboembolism in the elderly patient

Enrico Tincani, Mark A Crowther, Fabrizio Turrini, Domenico Prisco

Clinical Interventions in Aging 2007, 2:237-246

Published Date: 15 July 2007